Futura Medical PLC (OTCPK:FAMDF)

Half Year 2025 Futura Medical PLC Earnings Call Transcript

Sep 30, 2025 / 08:30 AM GMT

Release Date Price: $0.05

Transcript

Key Points

Positve

Futura Medical PLC (FAMDF) has launched its product Eroxon in 25 markets, including 7 new markets in H1 2025.
The company is actively working on two promising R&D projects: Project Intense and WSD 4,000, with regulatory approval for Project Intense expected by the end of 2025.
Cost reductions have been implemented, reducing core G&A costs from 3.4 million to 2.6 million.
Futura Medical PLC (FAMDF) is exploring commercial and financing options to extend its cash runway beyond January 2026.
The board remains confident in the long-term value of the group's assets and is committed to progressing development plans for Eroxon Intense and WSD 4,000.

Negative

The company's full-year 2025 performance is expected to be significantly below market expectations due to lower than anticipated repeat sales.
Futura Medical PLC (FAMDF) reported a loss after tax of 6.6 million for H1 2025, with an adjusted loss of 1.9 million.
Cash reserves are limited, with only 3.69 million at the end of H1 2025, providing a runway only into January 2026.
The US launch of Eroxon has not met initial expectations, with slower than anticipated repeat sales.
The company faces challenges in sustaining consumer uptake and repeat sales across all markets, impacting supply volumes and royalty streams.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

FUM.L - Futura Medical PLC
Half Year 2025 Futura Medical PLC Earnings Call
Sep 30, 2025 / 08:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the Futura Medical PLC Investor presentation. Throughout this recorded presentation, investors will be in lesson only mode. Questions are encouraged and they can be submitted at any time using the Q&A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review questions submitted today on publish responses which is appropriate to do so. Before we begin, I would like to submit the following poll, and I would now like to hand you over to interim CEO Alex Duggan. Good morning.

------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.